 <h1>Pyrimethamine Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to pyrimethamine: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, pyrimethamine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking pyrimethamine:</p><p>
<i>Less common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>blood in urine or stools</li>
<li>cough or hoarseness</li>
<li> fever or chills</li>
<li>irritation or soreness of tongue </li>
<li>lower back or side pain</li>
<li> painful or difficult urination</li>
<li>pinpoint red spots on skin</li>
<li>unusual bleeding or bruising</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Bleeding or crusting sores on lips</li>
<li> chest pain or discomfort</li>
<li>muscle cramps or pain</li>
<li>redness, blistering, peeling, or loosening of skin</li>
<li>skin rash</li>
<li>sores, ulcers, and/or white spots in mouth</li>
<li>sore throat</li>
<li> unusual tiredness or weakness</li>
</ul><p>
<i>Frequency not known</i>
</p><ul>
<li>Blood in urine</li>
<li>diarrhea</li>
<li>difficulty swallowing</li>
<li>dizziness</li>
<li>fainting spells</li>
<li>fast, slow, or irregular heartbeat</li>
<li>hives</li>
<li>itching </li>
<li>joint or muscle pain</li>
<li> lightheadedness</li>
<li>pale skin</li>
<li> pounding or rapid pulse</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips or tongue</li>
<li> rapid breathing</li>
<li>red, irritated eyes</li>
<li>red skin lesions, often with a purple center</li>
<li> shortness of breath</li>
<li>swollen glands</li>
<li>tightness in chest</li>
<li>unexplained bleeding or bruising</li>
<li>wheezing</li>
</ul><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>convulsions (seizures)</li>
<li>increased excitability</li>
<li>vomiting (severe and continuing)</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of pyrimethamine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Diarrhea</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>vomiting</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pyrimethamine: compounding powder, oral tablet</i></p><h3>General</h3><p>Since this drug is coadministered with a sulfonamide, the manufacturer product information for the relevant sulfonamide should be consulted for sulfonamide-related side effects.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea, vomiting, diarrhea, colic</p>
<p><b>Uncommon</b> (0.1% to 1%): Dry mouth, dry throat</p>
<p><b>Very rare</b> (less than 0.01%): Buccal ulceration</p>
<p><b>Frequency not reported</b>: Glossitis, atrophic glossitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Precipitation of a grand mal attack in a patient predisposed to epilepsy was reported; clinical significance was not established.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache</p>
<p><b>Common</b> (1% to 10%): Dizziness</p>
<p><b>Very rare</b> (less than 0.01%): Convulsions/seizures</p>
<p><b>Frequency not reported</b>: Ataxia, tremors, precipitation of grand mal attack<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia</p>
<p><b>Common</b> (1% to 10%): Thrombocytopenia, leukopenia</p>
<p><b>Very rare</b> (less than 0.01%): Pancytopenia</p>
<p><b>Frequency not reported</b>: Megaloblastic anemia, neutropenia, agranulocytosis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash</p>
<p><b>Uncommon</b> (0.1% to 1%): Abnormal skin pigmentation, dermatitis</p><h3>Other</h3><p><b>Uncommon</b> (0.1% to 1%): Fever, malaise</p><h3>Psychiatric</h3><p>Insomnia was reported when this drug was given weekly at higher than recommended doses.</p><p><b>Uncommon</b> (0.1% to 1%): Depression</p>
<p><b>Very rare</b> (less than 0.01%): Insomnia</p><h3>Respiratory</h3><p><b>Rare</b> (0.01% to 0.1%): Pulmonary eosinophilia</p>
<p><b>Very rare</b> (less than 0.01%): Pneumonia with cellular and eosinophilic pulmonary infiltration<sup>[Ref]</sup></p><p>Pneumonia with cellular and eosinophilic pulmonary infiltration was observed when this drug was administered once a week with sulfadoxine.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity reactions (included erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis, Lyell's syndrome, hepatitis, anaphylaxis, pulmonary reactions, maculopapular rashes)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Circulatory collapse was reported in patients treated with higher than recommended doses.<sup>[Ref]</sup></p><p><b>Very rare</b> (less than 0.01%): Circulatory collapse</p>
<p><b>Frequency not reported</b>: Disorders of cardiac rhythm, arrhythmias<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Hyperphenylalaninemia was reported in neonates treated for congenital toxoplasmosis.<sup>[Ref]</sup></p><p><b>Very rare</b> (less than 0.01%): Hyperphenylalaninemia</p>
<p><b>Frequency not reported</b>: Anorexia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very rare</b> (less than 0.01%): Hematuria</p><h3>Oncologic</h3><p>A 51-year-old female developed chronic granulocytic leukemia after taking this drug for 2 years for toxoplasmosis and a 56-year-old patient developed reticulum cell sarcoma after taking this drug for 14 months for toxoplasmosis.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Chronic granulocytic leukemia, reticulum cell sarcoma<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Daraprim (pyrimethamine)." Glaxo Wellcome, Research Triangle Park, NC. </p><p id="ref_4">4. Booth F, Barker LC, Barton CJ, Naik RB "Agranulocytosis during malaria prophylaxis with Maloprim (pyrimethamine and dapsone)." Postgrad Med J 60 (1984): 566-7</p><p id="ref_5">5. Iaccheri B,  Fiore T,  Papadaki T, et al. "Adverse drug reactions to treatments for ocular toxoplasmosis: A retrospective chart review." Clin Ther 30 (2008): 2069-74</p><p id="ref_6">6. Ree GH "Chemoprophylaxis of malaria in Africa." Br Med J (Clin Res Ed) 286 (1983): 562</p><p id="ref_7">7. Nicholls MD, Concannon AJ "Maloprim-induced agranulocytosis and red-cell aplasia." Med J Aust 2 (1982): 564-6</p><p id="ref_8">8. Phillips-Howard PA, West LJ "Serious adverse drug reactions to pyrimethamine-sulphadoxine pyrimethamine-dapsone and to amodiaquine in Britain." J R Soc Med 83 (1990): 82-5</p><p id="ref_9">9. Whitehead S "Agranulocytosis associated with maloprim." Br Med J (Clin Res Ed) 286 (1983): 1515</p><p id="ref_10">10. Olsen VV, Loft S, Christensen KD "Serious reactions during malaria prophylaxis with pyrimethamine- sulfadoxine." Lancet 2 (1982): 994</p><p id="ref_11">11. Bowcock SJ, Linch DC, Machin SJ, Stewart JW "Pyrimethamine in the myeloproliferative disorders: a forgotten treatment?" Clin Lab Haematol 9 (1987): 129-36</p><p id="ref_12">12. Davidson AC, Bateman C, Shovlin C, Marrinan M, Burton GH, Cameron IR "Pulmonary toxicity of malaria prophylaxis." BMJ 297 (1988): 1240-1</p><p id="ref_13">13. Pang JA "Non-cardiogenic pulmonary oedema associated with pyrimethamine." Respir Med 83 (1989): 247-8</p><p id="ref_14">14. Bamber MG, Elder AT, Gray JA, Minns RA "Fatal Stevens-Johnson syndrome associated with Fansidar and chloroquine." J Infect 13 (1986): 31-3</p><p id="ref_15">15. Hornstein OP, Ruprecht KW "Fansidar-induced Stevens-Johnson Syndrome." N Engl J Med 307 (1982): 1529-30</p><p id="ref_16">16. "Fansidar-associated fatal reaction in an HIV-infected man." MMWR Morb Mortal Wkly Rep 37 (1988): 571-2</p><p id="ref_17">17. Phillips-Howard PA, Behrens RH, Dunlop J "Stevens-Johnson syndrome due to pyrimethamine/sulfadoxine during presumptive self-therapy of malaria." Lancet 2 (1989): 803-4</p><p id="ref_18">18. Zitelli BJ, Alexander J, Taylor S, Miller KD, Howrie DL, Kuritsky JN, Perez TH, Van Thiel DH "Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar)." Ann Intern Med 106 (1987): 393-5</p><p id="ref_19">19. McCormack D, Morgan WK "Fansidar hypersensitivity pneumonitis." Br J Dis Chest 81 (1987): 194-6</p><p id="ref_20">20. Jeffrey RF "Transient lupus anticoagulant and fansidar therapy." Postgrad Med J 62 (1986): 893-4</p><p id="ref_21">21. Ward DJ, Krzeminska EC, Tanner NS "Treatment of toxic epidermal necrolysis and a review of six cases." Burns 16 (1990): 97-104</p><p id="ref_22">22. Svanbom M, Rombo L, Gustafsson L "Unusual pulmonary reaction during short term prophylaxis with pyrimethamine-sulfadoxine (Fansidar)." Br Med J (Clin Res Ed) 288 (1984): 1876</p><p id="ref_23">23. Selby CD, Ladusans EJ, Smith PG "Fatal multisystemic toxicity associated with prophylaxis with pyrimethamine and sulfadoxine (Fansidar)." Br Med J (Clin Res Ed) 290 (1985): 113-4</p><p id="ref_24">24. Ortel B, Sivayathorn A, Honigsmann H "An unusual combination of phototoxicity and Stevens-Johnson syndrome due to antimalarial therapy." Dermatologica 178 (1989): 39-42</p><p id="ref_25">25. Whitfield D "Presumptive fatality due to pyrimethamine-sulfadoxine." Lancet 2 (1982): 1272</p><p id="ref_26">26. Adams SJ, Broadbent J, Clayden LM, Ridley CM "Erythema multiforme (Stevens-Johnson) precipitated by Fansidar." Postgrad Med J 61 (1985): 263-4</p></div>
<div class="more-resources" id="moreResources">
<h2>More about pyrimethamine</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: miscellaneous antimalarials</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Pyrimethamine &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Daraprim</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Malaria Prevention</li>
<li>Pneumocystis Pneumonia Prophylaxis</li>
<li>Toxoplasmosis</li>
<li>Toxoplasmosis, Prophylaxis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pyrimethamine: compounding powder, oral tablet</i></p><h3>General</h3><p>Since this drug is coadministered with a sulfonamide, the manufacturer product information for the relevant sulfonamide should be consulted for sulfonamide-related side effects.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea, vomiting, diarrhea, colic</p><p><b>Uncommon</b> (0.1% to 1%): Dry mouth, dry throat</p><p><b>Very rare</b> (less than 0.01%): Buccal ulceration</p><p><b>Frequency not reported</b>: Glossitis, atrophic glossitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Precipitation of a grand mal attack in a patient predisposed to epilepsy was reported; clinical significance was not established.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache</p><p><b>Common</b> (1% to 10%): Dizziness</p><p><b>Very rare</b> (less than 0.01%): Convulsions/seizures</p><p><b>Frequency not reported</b>: Ataxia, tremors, precipitation of grand mal attack<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia</p><p><b>Common</b> (1% to 10%): Thrombocytopenia, leukopenia</p><p><b>Very rare</b> (less than 0.01%): Pancytopenia</p><p><b>Frequency not reported</b>: Megaloblastic anemia, neutropenia, agranulocytosis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash</p><p><b>Uncommon</b> (0.1% to 1%): Abnormal skin pigmentation, dermatitis</p><h3>Other</h3><p><b>Uncommon</b> (0.1% to 1%): Fever, malaise</p><h3>Psychiatric</h3><p>Insomnia was reported when this drug was given weekly at higher than recommended doses.</p><p><b>Uncommon</b> (0.1% to 1%): Depression</p><p><b>Very rare</b> (less than 0.01%): Insomnia</p><h3>Respiratory</h3><p><b>Rare</b> (0.01% to 0.1%): Pulmonary eosinophilia</p><p><b>Very rare</b> (less than 0.01%): Pneumonia with cellular and eosinophilic pulmonary infiltration<sup>[Ref]</sup></p><p>Pneumonia with cellular and eosinophilic pulmonary infiltration was observed when this drug was administered once a week with sulfadoxine.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity reactions (included erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis, Lyell's syndrome, hepatitis, anaphylaxis, pulmonary reactions, maculopapular rashes)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Circulatory collapse was reported in patients treated with higher than recommended doses.<sup>[Ref]</sup></p><p><b>Very rare</b> (less than 0.01%): Circulatory collapse</p><p><b>Frequency not reported</b>: Disorders of cardiac rhythm, arrhythmias<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Hyperphenylalaninemia was reported in neonates treated for congenital toxoplasmosis.<sup>[Ref]</sup></p><p><b>Very rare</b> (less than 0.01%): Hyperphenylalaninemia</p><p><b>Frequency not reported</b>: Anorexia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very rare</b> (less than 0.01%): Hematuria</p><h3>Oncologic</h3><p>A 51-year-old female developed chronic granulocytic leukemia after taking this drug for 2 years for toxoplasmosis and a 56-year-old patient developed reticulum cell sarcoma after taking this drug for 14 months for toxoplasmosis.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Chronic granulocytic leukemia, reticulum cell sarcoma<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Daraprim (pyrimethamine)." Glaxo Wellcome, Research Triangle Park, NC. </p><p id="ref_4">4. Booth F, Barker LC, Barton CJ, Naik RB "Agranulocytosis during malaria prophylaxis with Maloprim (pyrimethamine and dapsone)." Postgrad Med J 60 (1984): 566-7</p><p id="ref_5">5. Iaccheri B,  Fiore T,  Papadaki T, et al. "Adverse drug reactions to treatments for ocular toxoplasmosis: A retrospective chart review." Clin Ther 30 (2008): 2069-74</p><p id="ref_6">6. Ree GH "Chemoprophylaxis of malaria in Africa." Br Med J (Clin Res Ed) 286 (1983): 562</p><p id="ref_7">7. Nicholls MD, Concannon AJ "Maloprim-induced agranulocytosis and red-cell aplasia." Med J Aust 2 (1982): 564-6</p><p id="ref_8">8. Phillips-Howard PA, West LJ "Serious adverse drug reactions to pyrimethamine-sulphadoxine pyrimethamine-dapsone and to amodiaquine in Britain." J R Soc Med 83 (1990): 82-5</p><p id="ref_9">9. Whitehead S "Agranulocytosis associated with maloprim." Br Med J (Clin Res Ed) 286 (1983): 1515</p><p id="ref_10">10. Olsen VV, Loft S, Christensen KD "Serious reactions during malaria prophylaxis with pyrimethamine- sulfadoxine." Lancet 2 (1982): 994</p><p id="ref_11">11. Bowcock SJ, Linch DC, Machin SJ, Stewart JW "Pyrimethamine in the myeloproliferative disorders: a forgotten treatment?" Clin Lab Haematol 9 (1987): 129-36</p><p id="ref_12">12. Davidson AC, Bateman C, Shovlin C, Marrinan M, Burton GH, Cameron IR "Pulmonary toxicity of malaria prophylaxis." BMJ 297 (1988): 1240-1</p><p id="ref_13">13. Pang JA "Non-cardiogenic pulmonary oedema associated with pyrimethamine." Respir Med 83 (1989): 247-8</p><p id="ref_14">14. Bamber MG, Elder AT, Gray JA, Minns RA "Fatal Stevens-Johnson syndrome associated with Fansidar and chloroquine." J Infect 13 (1986): 31-3</p><p id="ref_15">15. Hornstein OP, Ruprecht KW "Fansidar-induced Stevens-Johnson Syndrome." N Engl J Med 307 (1982): 1529-30</p><p id="ref_16">16. "Fansidar-associated fatal reaction in an HIV-infected man." MMWR Morb Mortal Wkly Rep 37 (1988): 571-2</p><p id="ref_17">17. Phillips-Howard PA, Behrens RH, Dunlop J "Stevens-Johnson syndrome due to pyrimethamine/sulfadoxine during presumptive self-therapy of malaria." Lancet 2 (1989): 803-4</p><p id="ref_18">18. Zitelli BJ, Alexander J, Taylor S, Miller KD, Howrie DL, Kuritsky JN, Perez TH, Van Thiel DH "Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar)." Ann Intern Med 106 (1987): 393-5</p><p id="ref_19">19. McCormack D, Morgan WK "Fansidar hypersensitivity pneumonitis." Br J Dis Chest 81 (1987): 194-6</p><p id="ref_20">20. Jeffrey RF "Transient lupus anticoagulant and fansidar therapy." Postgrad Med J 62 (1986): 893-4</p><p id="ref_21">21. Ward DJ, Krzeminska EC, Tanner NS "Treatment of toxic epidermal necrolysis and a review of six cases." Burns 16 (1990): 97-104</p><p id="ref_22">22. Svanbom M, Rombo L, Gustafsson L "Unusual pulmonary reaction during short term prophylaxis with pyrimethamine-sulfadoxine (Fansidar)." Br Med J (Clin Res Ed) 288 (1984): 1876</p><p id="ref_23">23. Selby CD, Ladusans EJ, Smith PG "Fatal multisystemic toxicity associated with prophylaxis with pyrimethamine and sulfadoxine (Fansidar)." Br Med J (Clin Res Ed) 290 (1985): 113-4</p><p id="ref_24">24. Ortel B, Sivayathorn A, Honigsmann H "An unusual combination of phototoxicity and Stevens-Johnson syndrome due to antimalarial therapy." Dermatologica 178 (1989): 39-42</p><p id="ref_25">25. Whitfield D "Presumptive fatality due to pyrimethamine-sulfadoxine." Lancet 2 (1982): 1272</p><p id="ref_26">26. Adams SJ, Broadbent J, Clayden LM, Ridley CM "Erythema multiforme (Stevens-Johnson) precipitated by Fansidar." Postgrad Med J 61 (1985): 263-4</p><h2>More about pyrimethamine</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: miscellaneous antimalarials</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Pyrimethamine &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Malaria Prevention</li>
<li>Pneumocystis Pneumonia Prophylaxis</li>
<li>Toxoplasmosis</li>
<li>Toxoplasmosis, Prophylaxis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>